cIAP1, cIAP2, and XIAP act cooperatively via nonredundant pathways to regulate Genotoxic stress–induced nuclear factor-κB activation HS Jin, DH Lee, DH Kim, JH Chung, SJ Lee, TH Lee Cancer research 69 (5), 1782-1791, 2009 | 135 | 2009 |
TSC1 regulates the balance between effector and regulatory T cells Y Park, HS Jin, J Lopez, C Elly, G Kim, M Murai, M Kronenberg, YC Liu The Journal of clinical investigation 123 (12), 5165-5178, 2013 | 132 | 2013 |
Itch expression by Treg cells controls Th2 inflammatory responses H Jin, Y Park, C Elly, YC Liu The Journal of clinical investigation 123 (11), 4923-4934, 2013 | 94 | 2013 |
TIGIT/CD226 axis regulates anti-tumor immunity J Yeo, M Ko, DH Lee, Y Park, H Jin Pharmaceuticals 14 (3), 200, 2021 | 89 | 2021 |
The ubiquitin system in immune regulation Y Park, H Jin, D Aki, J Lee, YC Liu Advances in immunology 124, 17-66, 2014 | 81 | 2014 |
Neddylation pathway regulates T-cell function by targeting an adaptor protein Shc and a protein kinase Erk signaling H Jin, L Liao, Y Park, YC Liu Proceedings of the National Academy of Sciences 110 (2), 624-629, 2013 | 81 | 2013 |
CD226hiCD8+ T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy H Jin, M Ko, D Choi, JH Kim, D Lee, SH Kang, I Kim, HJ Lee, EK Choi, ... Cancer immunology research 8 (7), 912-925, 2020 | 68 | 2020 |
Regulation of T cell function by the ubiquitin-specific protease USP9X via modulating the Carma1-Bcl10-Malt1 complex Y Park, H Jin, YC Liu Proceedings of the National Academy of Sciences 110 (23), 9433-9438, 2013 | 65 | 2013 |
SHARPIN controls regulatory T cells by negatively modulating the T cell antigen receptor complex Y Park, H Jin, J Lopez, J Lee, L Liao, C Elly, YC Liu Nature immunology 17 (3), 286-296, 2016 | 58 | 2016 |
Mucin1 and Mucin16: therapeutic targets for cancer therapy DH Lee, S Choi, Y Park, H Jin Pharmaceuticals 14 (10), 1053, 2021 | 49 | 2021 |
Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy H Jin, Y Park BMB reports 54 (1), 2, 2021 | 47 | 2021 |
LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation E Sung, M Ko, J Won, Y Jo, E Park, H Kim, E Choi, U Jung, J Jeon, Y Kim, ... Molecular Therapy 30 (8), 2800-2816, 2022 | 38 | 2022 |
A novel inhibitor of apoptosis protein (IAP)-interacting protein, Vestigial-like (Vgl)-4, counteracts apoptosis-inhibitory function of IAPs by nuclear sequestration HS Jin, HS Park, JH Shin, DH Kim, SH Jun, CJ Lee, TH Lee Biochemical and biophysical research communications 412 (3), 454-459, 2011 | 35 | 2011 |
Cell cycle-dependent expression of cIAP2 at G2/M phase contributes to survival during mitotic cell cycle arrest HS Jin, TH Lee Biochemical Journal 399 (2), 335-342, 2006 | 35 | 2006 |
Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis C Yoo, SS Lee, KB Song, JH Jeong, J Hyung, DH Park, TJ Song, DW Seo, ... British Journal of Cancer 123 (3), 362-368, 2020 | 34 | 2020 |
Extracellular pH modulating injectable gel for enhancing immune checkpoint inhibitor therapy H Jin, D Choi, M Ko, D Kim, D Lee, S Lee, AY Lee, SG Kang, SH Kim, ... Journal of controlled release 315, 65-75, 2019 | 26 | 2019 |
IL-4 augments anisomycin-induced p38 activation via Akt pathway in a follicular dendritic cell (FDC)-like line HM Lee, HS Jin, JW Park, SM Park, HK Jeon, TH Lee FEBS letters 549 (1-3), 110-114, 2003 | 19 | 2003 |
Proteome analysis associated with cadmium adaptation in U937 cells: identification of calbindin-D28k as a secondary cadmium-responsive protein that confers resistance to … HK Jeon, HS Jin, DH Lee, WS Choi, CK Moon, YJ Oh, TH Lee Journal of Biological Chemistry 279 (30), 31575-31583, 2004 | 18 | 2004 |
Genome wide CRISPR screening reveals a role for sialylation in the tumorigenesis and chemoresistance of acute myeloid leukemia cells D Lee, SH Kang, D Choi, M Ko, E Choi, H Ahn, H Min, SJ Oh, MS Lee, ... Cancer Letters 510, 37-47, 2021 | 11 | 2021 |
Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors N Kim, DH Lee, WS Choi, E Yi, HJ Kim, JM Kim, HS Jin, HS Kim BMB reports 54 (1), 44, 2021 | 10 | 2021 |